UY35445A - Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral - Google Patents

Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral

Info

Publication number
UY35445A
UY35445A UY35445A UY35445A UY35445A UY 35445 A UY35445 A UY 35445A UY 35445 A UY35445 A UY 35445A UY 35445 A UY35445 A UY 35445A UY 35445 A UY35445 A UY 35445A
Authority
UY
Uruguay
Prior art keywords
testosterone
lipoequilibrated
oral administration
long chain
composition
Prior art date
Application number
UY35445A
Other languages
English (en)
Inventor
Giliyar Chandrashekar
Nachiappan Chidambaram
Mahesh V Patel
Patel Raj
Satish Kumar Nachaegarj
Srinivansan Venkateshwaran
Original Assignee
Lipocine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/843,403 external-priority patent/US20130225544A1/en
Application filed by Lipocine Inc filed Critical Lipocine Inc
Publication of UY35445A publication Critical patent/UY35445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmaceuticas y formas farmaceuticas orales que contienen esteres de testosterona seleccionados y a metodos relacionados. Una realizacion de la invencion, proporciona una composicion oral para administracion a sujetos que necesitan testosterona. La composicion comprende un ester de testosterona y un portador farmaceuticamente aceptable . El ester de testosterona puede tenerr la estructura en la que R es -CH13H25O o -CH14H27O. Uno o ambos eteres pueden estar presentes en la composicion. Tras la administracion de dosis unica, la composicion proporciona una Cprom. T12-T24 de testosterona en suero media que esta dentro de aproximadamente el 35% a el 70% de la Cprom t0-t24 de testosterona en suero media.
UY35445A 2013-03-15 2014-03-14 Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral UY35445A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/843,403 US20130225544A1 (en) 2009-01-08 2013-03-15 Lipobalanced long chain testosterone esters for oral delivery

Publications (1)

Publication Number Publication Date
UY35445A true UY35445A (es) 2014-10-31

Family

ID=51538095

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35445A UY35445A (es) 2013-03-15 2014-03-14 Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral

Country Status (16)

Country Link
US (2) US20160193227A1 (es)
EP (2) EP3797762A1 (es)
JP (1) JP6307711B2 (es)
KR (1) KR102238478B1 (es)
CN (1) CN105073118A (es)
AR (1) AR095538A1 (es)
AU (2) AU2014232475A1 (es)
BR (1) BR112015020849A2 (es)
CA (1) CA2942005C (es)
IL (1) IL240958B (es)
MX (1) MX2015010594A (es)
RU (1) RU2722592C2 (es)
TW (1) TW201521731A (es)
UY (1) UY35445A (es)
WO (1) WO2014145781A1 (es)
ZA (1) ZA201507700B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102618A1 (en) 2016-11-30 2018-06-07 Lipocine Inc. Oral testosterone tridecanoate therapy
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
WO2024005770A1 (en) * 2022-06-22 2024-01-04 Lipocine, Inc. (17-)-3-oxoandrost-4-en-17-yl dodecanoate compositions and methods of preparation and use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL189235C (nl) * 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
GB1567515A (en) * 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
ATE311201T1 (de) * 2000-08-23 2005-12-15 Akzo Nobel Nv Testosteron-ester formulierung zur anwendung am menschen
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
RU2429850C2 (ru) * 2005-04-15 2011-09-27 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
CN101217963A (zh) * 2005-04-15 2008-07-09 克劳拉斯医疗有限公司 疏水性药物给药系统及含有疏水性药物的组合物
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions

Also Published As

Publication number Publication date
IL240958A0 (en) 2015-11-30
MX2015010594A (es) 2015-12-16
WO2014145781A1 (en) 2014-09-18
KR20150129671A (ko) 2015-11-20
EP2968363A1 (en) 2016-01-20
JP2016514706A (ja) 2016-05-23
US20160193227A1 (en) 2016-07-07
CN105073118A (zh) 2015-11-18
RU2722592C2 (ru) 2020-06-02
JP6307711B2 (ja) 2018-04-11
CA2942005A1 (en) 2014-09-18
BR112015020849A2 (pt) 2017-07-18
TW201521731A (zh) 2015-06-16
EP2968363B1 (en) 2020-08-19
CA2942005C (en) 2022-02-01
ZA201507700B (en) 2017-02-22
AR095538A1 (es) 2015-10-21
RU2015128028A (ru) 2017-04-21
IL240958B (en) 2019-07-31
EP3797762A1 (en) 2021-03-31
AU2019200097B2 (en) 2021-02-04
US20160193228A1 (en) 2016-07-07
EP2968363A4 (en) 2016-08-17
KR102238478B1 (ko) 2021-04-09
AU2014232475A1 (en) 2015-08-06
AU2019200097A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CL2016000508A1 (es) Compuestos derivados de (2-metil-3-fenilfenil)metoxi sustituidos, inhibidores de la interacción pd-1/proteína pd-l1/proteína; composición farmacéutica que los comprende; y su uso para tratar una enfermedad infecciosa o cáncer.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
GT201400261A (es) Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
NI201400042A (es) 2 - tiopirimidinonas
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
NZ628079A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
UY35445A (es) Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112